Filing Flows › TG Therapeutics (TGTX) › Q2 2025
TG Therapeutics (TGTX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 8, 2025
TG Therapeutics (TGTX) reported revenue of $141M for the second quarter 2025 (Q2 2025), +92% from a year earlier and +17% from the quarter before. Operating margin was 24.7%, net earnings $28.2M (20.0% of revenue).
TG Therapeutics, Q2 2025: revenue $141M (+92% year over year), operating margin 24.7%, net earnings $28.2M, operating cash flow $7.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $141M | +17% | +92% |
| Operating profit | $34.8M | +304% | +295% |
| Net earnings | $28.2M | +457% | +310% |
| Operating cash flow | $7.4M | — | +34% |
| Free cash flow | $7.4M | — | +34% |
What changed
Revenue was $141.1M in Q2 2025, up 92% year over year and up 17% from the previous quarter. Product was the largest line at 98% of revenue. Product added $66.2M year over year (up 91%), 98% of the total change.
Operating profit was $34.8M, a 24.7% margin (up 12.7 points year over year). Of the extra revenue versus a year earlier, 38% reached operating profit, above the 12% margin then. Total costs grew 64% against revenue growth of 92%. The fastest-growing cost line was Cost of revenue (+128%). Net earnings were $28.2M, up 310% year over year. The effective tax rate was 8.8%.
Operating cash flow was $7.4M (up 34% year over year), 26% of net earnings. Non-cash charges added back $13K of depreciation and amortization and $16.4M of share-based compensation. Working capital and other items used $37.1M. Capital expenditures of $42K left free cash flow of $7.4M.
Questions
What was TG Therapeutics' revenue in the second quarter 2025?
TG Therapeutics (TGTX) reported revenue of $141M for the second quarter 2025 (Q2 2025), +92% from a year earlier and +17% from the quarter before.
Was TG Therapeutics profitable in the second quarter 2025?
Operating profit was $34.8M (24.7% of revenue) and net earnings $28.2M.
Source: TG Therapeutics 10-Q on SEC EDGAR.